SonoScape Medical Corp.

SZSE:300633 Stock Report

Market Cap: CN¥15.0b

SonoScape Medical Valuation

Is 300633 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300633 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300633 (CN¥34.51) is trading below our estimate of fair value (CN¥41.45)

Significantly Below Fair Value: 300633 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300633?

Key metric: As 300633 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300633. This is calculated by dividing 300633's market cap by their current earnings.
What is 300633's PE Ratio?
PE Ratio61.2x
EarningsCN¥242.81m
Market CapCN¥14.98b

Price to Earnings Ratio vs Peers

How does 300633's PE Ratio compare to its peers?

The above table shows the PE ratio for 300633 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average76.4x
688301 iRay Technology
28.2x27.5%CN¥16.0b
688198 Beijing Balance Medical TechnologyLtd
154.7x41.1%CN¥16.1b
300298 Sinocare
58.5x34.9%CN¥13.0b
600055 Beijing Wandong Medical TechnologyLtd
64.2xn/aCN¥12.1b
300633 SonoScape Medical
61.2x55.2%CN¥15.0b

Price-To-Earnings vs Peers: 300633 is good value based on its Price-To-Earnings Ratio (61.2x) compared to the peer average (76.4x).

Price to Earnings Ratio vs Industry

How does 300633's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300633 61.2xIndustry Avg. 35.0xNo. of Companies17PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300633 is expensive based on its Price-To-Earnings Ratio (61.2x) compared to the CN Medical Equipment industry average (35x).

Price to Earnings Ratio vs Fair Ratio

What is 300633's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300633 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.2x
Fair PE Ratio54.8x

Price-To-Earnings vs Fair Ratio: 300633 is expensive based on its Price-To-Earnings Ratio (61.2x) compared to the estimated Fair Price-To-Earnings Ratio (54.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300633 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥34.51
CN¥42.42
+22.9%
9.1%CN¥49.40CN¥37.65n/a5
Nov ’25CN¥35.81
CN¥43.87
+22.5%
6.2%CN¥49.40CN¥40.93n/a7
Oct ’25CN¥36.31
CN¥46.35
+27.6%
12.2%CN¥58.00CN¥41.02n/a7
Sep ’25CN¥30.60
CN¥47.20
+54.3%
11.4%CN¥58.00CN¥41.02n/a7
Aug ’25CN¥34.66
CN¥48.80
+40.8%
10.1%CN¥58.00CN¥42.57n/a7
Jul ’25CN¥38.08
CN¥49.46
+29.9%
9.8%CN¥58.00CN¥42.57n/a6
Jun ’25CN¥39.19
CN¥49.46
+26.2%
9.8%CN¥58.00CN¥42.57n/a6
May ’25CN¥41.30
CN¥49.46
+19.7%
9.8%CN¥58.00CN¥42.57n/a6
Apr ’25CN¥37.54
CN¥54.40
+44.9%
9.7%CN¥60.00CN¥45.50n/a6
Mar ’25CN¥38.97
CN¥57.34
+47.1%
13.9%CN¥67.50CN¥45.50n/a6
Feb ’25CN¥35.09
CN¥57.34
+63.4%
13.9%CN¥67.50CN¥45.50n/a6
Jan ’25CN¥47.30
CN¥57.34
+21.2%
13.9%CN¥67.50CN¥45.50n/a6
Dec ’24CN¥51.59
CN¥58.96
+14.3%
13.1%CN¥67.50CN¥45.50n/a5
Nov ’24CN¥48.43
CN¥59.35
+22.6%
12.0%CN¥67.50CN¥45.50CN¥35.816
Oct ’24CN¥48.77
CN¥62.43
+28.0%
8.1%CN¥70.00CN¥54.88CN¥36.316
Sep ’24CN¥45.15
CN¥63.31
+40.2%
8.0%CN¥70.00CN¥54.88CN¥30.605
Aug ’24CN¥45.24
CN¥67.40
+49.0%
6.7%CN¥73.00CN¥61.31CN¥34.665
Jul ’24CN¥54.50
CN¥67.40
+23.7%
6.7%CN¥73.00CN¥61.31CN¥38.085
Jun ’24CN¥57.98
CN¥67.40
+16.3%
6.7%CN¥73.00CN¥61.31CN¥39.195
May ’24CN¥54.70
CN¥67.40
+23.2%
6.7%CN¥73.00CN¥61.31CN¥41.305
Apr ’24CN¥55.36
CN¥66.15
+19.5%
9.6%CN¥72.50CN¥56.56CN¥37.544
Mar ’24CN¥47.14
CN¥64.04
+35.8%
9.3%CN¥71.16CN¥56.56CN¥38.973
Feb ’24CN¥53.01
CN¥64.04
+20.8%
9.3%CN¥71.16CN¥56.56CN¥35.093
Jan ’24CN¥54.83
CN¥63.86
+16.5%
11.4%CN¥71.16CN¥56.56CN¥47.302
Dec ’23CN¥53.00
CN¥63.86
+20.5%
11.4%CN¥71.16CN¥56.56CN¥51.592

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.8b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.77

7D

-3.4%

1Y

-34.8%

Chison Medical Technologies

CN¥2.7b

Manufactures and sells diagnostic ultrasound systems in China and internationally.

688358

CN¥25.71

7D

3.4%

1Y

-42.1%

Innovita Biological Technology

CN¥5.7b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥41.42

7D

1.5%

1Y

35.8%